Module 4: From Signal to Strategy: Interpreting In Vivo Micronucleus and Comet Assay Results
Recorded On: 05/27/2027
This presentation focuses on the role of in vivo genetic toxicology assays within the nonclinical safety assessment of pharmaceuticals, with emphasis on in vivo micronucleus and in vivo comet assays. These assays are critical tools for evaluating clastogenic, aneugenic, and DNA‑damaging potential in the context of whole‑animal exposure and metabolism. The session reviews the scientific rationale, strengths, and limitations of each assay and discusses how positive findings are interpreted within a weight‑of‑evidence framework. Key topics include the ramifications of a positive in vivo result, strategies for confirmatory or follow‑up testing, and factors influencing assay selection, study design, and tissue targeting. Regulatory expectations and implications under relevant global guidance are addressed, including how in vivo data can impact development timelines, risk assessment, and regulatory decision making. The presentation concludes with a case study illustrating a practical approach to navigating a positive in vivo genetic toxicology finding, highlighting data integration, mechanistic considerations, communication with regulators, and potential paths forward. Participants will gain practical insights into applying these assays to support informed, science‑based decision making in drug development.
Wen Sun, PhD
Director of Genetic Toxicology
Pfizer Inc.
Dr. Wen Sun is the director of the Genetic Toxicology department at Pfizer. She received her PhD in Molecular and Cellular Biology from the University of Iowa and worked as a postdoctoral researcher in the Pharmacology Department at Yale University prior to joining Pfizer seven years ago. Currently, Dr. Sun oversees all scientific and strategic development of genetox at Pfizer, provides subject-matter expertise, and guides teams and chemists away from genotoxicity liabilities. Dr. Sun leads numerous working groups within the Health and Environmental Sciences Institute, focusing on the use of NAM-based approaches in hazard ID and risk management. Dr. Sun has been a long-time member of GTA and currently serves on the board of directors of the Environmental Mutagenesis and Genomics Society.